Approvals· September 3, 2026 · 34 min read
Injectafer's Phosphate Boxed Warning Does Not Rewrite J1439, AP Generics, or Oral-Iron PAs
By Ran Chen#Boxed Warning#Label Warnings#FDA Approval
Topic
Generic Entry
ANDA approvals, authorized generics, generic launch sequencing, patent expiry, and formulary shifts after generic entry.
Specialty· August 31, 2026 · 36 min read
Generic Erleada (Apalutamide): U.S. Entry, Patents, and Launch Signals
By Ran Chen#Oncology#Generic Entry#Orange Book
Generics· August 20, 2026 · 17 min read
Xcopri's First Generic Settlement: Reading the Cenobamate Patent Fence
By Ran Chen#Generics#Orange Book#Generic Entry
Generics· August 18, 2026 · 14 min read
Generic Wakix Approved but Cannot Launch Until 2030: The Orange Book Fence
By Ran Chen#Orange Book#Generics#Generic Entry
Specialty· August 15, 2026 · 23 min read
Prostate Cancer Treatment Access Landscape: Xtandi Patent Wall & Generics
By Ran Chen#Oncology#Generic Entry#Orange Book
Specialty· August 9, 2026 · 17 min read
Alopecia Areata Treatment Access (2026): Litfulo, Leqselvi, and Olumiant
Pricing & Access· August 3, 2026 · 15 min read
EU Pharmaceutical Procurement by the Numbers (2026): What 35,000 TED Tenders Reveal
By Ran Chen#Market Access#Generic Drugs#Drug Pricing
Generics· July 15, 2026 · 29 min read
2026–2027 Generic Launch Scorecard: Which Patent Cliffs Are Worth Filing
By Ran Chen#Orange Book#Generic Entry#ANDA Approval
Pricing & Access· July 15, 2026 · 19 min read
IPF Access Landscape 2026: Jascayd, Ofev Generic entry, and Pirfenidone Pricing
Policy· July 15, 2026 · 22 min read
The Post-CREATES REMS Moat Map: Safety Programs Shielding Brands After the Fix
By Ran Chen#REMS#Biosimilars#Generic Entry